Garofalo, M.; Bertinato, L.; Staniszewska, M.; Wieczorek, M.; Salmaso, S.; Schrom, S.; Rinner, B.; Pancer, K.W.; Kuryk, L.
Combination Therapy of Novel Oncolytic Adenovirus with Anti-PD1 Resulted in Enhanced Anti-Cancer Effect in Syngeneic Immunocompetent Melanoma Mouse Model. Pharmaceutics 2021, 13, 547.
https://doi.org/10.3390/pharmaceutics13040547
AMA Style
Garofalo M, Bertinato L, Staniszewska M, Wieczorek M, Salmaso S, Schrom S, Rinner B, Pancer KW, Kuryk L.
Combination Therapy of Novel Oncolytic Adenovirus with Anti-PD1 Resulted in Enhanced Anti-Cancer Effect in Syngeneic Immunocompetent Melanoma Mouse Model. Pharmaceutics. 2021; 13(4):547.
https://doi.org/10.3390/pharmaceutics13040547
Chicago/Turabian Style
Garofalo, Mariangela, Laura Bertinato, Monika Staniszewska, Magdalena Wieczorek, Stefano Salmaso, Silke Schrom, Beate Rinner, Katarzyna Wanda Pancer, and Lukasz Kuryk.
2021. "Combination Therapy of Novel Oncolytic Adenovirus with Anti-PD1 Resulted in Enhanced Anti-Cancer Effect in Syngeneic Immunocompetent Melanoma Mouse Model" Pharmaceutics 13, no. 4: 547.
https://doi.org/10.3390/pharmaceutics13040547
APA Style
Garofalo, M., Bertinato, L., Staniszewska, M., Wieczorek, M., Salmaso, S., Schrom, S., Rinner, B., Pancer, K. W., & Kuryk, L.
(2021). Combination Therapy of Novel Oncolytic Adenovirus with Anti-PD1 Resulted in Enhanced Anti-Cancer Effect in Syngeneic Immunocompetent Melanoma Mouse Model. Pharmaceutics, 13(4), 547.
https://doi.org/10.3390/pharmaceutics13040547